Close X
Attorney Spotlight

How did an interest in healthcare policy lead Robert Platt to a career in the law? Find out more>

Search

Close X

Experience

Search our Experience

Experience Spotlight

Envision to Sell to KKR for $9.9 Billion

We represented Envision Healthcare Corporation (NYSE: EVHC) in its definitive agreement to sell to KKR in an all-cash transaction for $9.9 billion, including debt. KKR will pay $46 per Envision share in cash to buy the company, marking a 32 percent premium to the company's volume-weighted average share price from November 1, when Envision announced it was considering its options. The transaction is expected to close the fourth quarter of 2018. Read more


Envision Healthcare

Close X

Thought Leadership

Enter your search terms in the relevant box(es) below to search for specific Thought Leadership.
To see a recent listing of Thought Leadership, click the blue Search button below.

Thought Leadership Spotlight

Six Things to Know Before Buying a Physician Practice spotlight

Dermatology, ophthalmology, radiology, urology…the list goes on. Yet, in any physician practice management transaction, there are six key considerations that apply and, if not carefully managed, can derail a transaction. Download the 6 Things to Know Before Buying a Physician Practice to keep your physician practice management transactions on track.

Click here to download the guide.

AmSurg Corp Merges with Envision Healthcare

Client Type: Public Company

We represented AmSurg Corp. (NASDAQ: AMSG) in its merger with Envision Healthcare Holdings, Inc. The combination of Envision Healthcare and AMSURG brings together two leading, complementary healthcare companies to form one of the nation's largest provider organizations. The combined organization will have a pro forma market capitalization of approximately $10 billion and enterprise value of approximately $15 billion based on the closing stock prices of Envision and AMSURG on June 14, 2016.

Envision Healthcare Corporation is co-headquartered in Nashville, Tennessee, and Greenwood Village, Colorado. The company’s common stock will begin trading on the New York Stock Exchange tomorrow, December 2, 2016, under the ticker symbol EVHC and will become part of the S&P 500 stock index.

The new Envision is the leading provider of physician-led services, ambulatory surgery center management, post-acute care and medical transportation. The company manages a highly differentiated suite of clinical solutions to support health systems, communities and payors, is composed of a significantly diversified business mix of specialties, customers and geographies, and provides a broader continuum of patient care.

Bass, Berry & Sims served as lead counsel on the transaction, led by Jim Jenkins. Additional details about the definitive merger agreement can be found in the official news release posted on Envision's website.

Award iconThis transaction was one of six separate deals involving Bass, Berry & Sims that was recognized as a Finalist for the 16th Annual M&A Advisor Awards in the categories of 

    • M&A Deal of the Year (over $5B)
    • Corporate/Strategic Deal of the Year (over $1B) 
    • Healthcare and Life Sciences Deal of the Year (over $100MM)

You Also May Be Interested In:

Related Professionals

Related Services

Notice

Visiting, or interacting with, this website does not constitute an attorney-client relationship. Although we are always interested in hearing from visitors to our website, we cannot accept representation on a new matter from either existing clients or new clients until we know that we do not have a conflict of interest that would prevent us from doing so. Therefore, please do not send us any information about any new matter that may involve a potential legal representation until we have confirmed that a conflict of interest does not exist and we have expressly agreed in writing to the representation. Until there is such an agreement, we will not be deemed to have given you any advice, any information you send may not be deemed privileged and confidential, and we may be able to represent adverse parties.